Dallis v. Aetna Life Insurance

574 F. Supp. 547, 1983 U.S. Dist. LEXIS 12003
CourtDistrict Court, N.D. Georgia
DecidedNovember 3, 1983
DocketCiv. A. C82-910A
StatusPublished
Cited by5 cases

This text of 574 F. Supp. 547 (Dallis v. Aetna Life Insurance) is published on Counsel Stack Legal Research, covering District Court, N.D. Georgia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dallis v. Aetna Life Insurance, 574 F. Supp. 547, 1983 U.S. Dist. LEXIS 12003 (N.D. Ga. 1983).

Opinion

ORDER

ROBERT H. HALL, District Judge.

The present case stems from the refusal of defendant, Aetna Life Insurance Company, to reimburse- the plaintiff for bills incurred in the treatment of plaintiffs wife’s cancer. Jurisdiction is predicated upon diversity of citizenship, 28 U.S.C. § 1332. The case is presently before this court on defendant’s motion for summary judgment. For the'reasons stated hereinafter defendant’s motion is DENIED in part, GRANTED in part.

FACTS

Park A. Dallis is an employee 1 of DeKalb County, Georgia. Both he and his wife, Jacqueline C. Dallis (now deceased), 2 are covered under the terms and provisions of a group health insurance policy issued by defendant, Aetna Life Insurance Company, to DeKalb County.

In November, 1974 Ms. Dallis underwent surgery for the removal of a malignant tumor, diagnosed as “adrenal carcinoma.” In November, 1977 Ms. Dallis again underwent cancer surgery. In April, 1978 Ms. Dallis began a treatment program of chemotherapy under the care of Dr. Ralph Vogler, a hematologist at Emory University Clinic. This treatment continued until January of 1979, when Dr. Vogler advised Ms. Dallis that in his opinion the treatment was non-productive. Shortly after discontinuing the chemotherapy Ms. Dallis enrolled in a nutritional therapy program offered by Dr. Kelly, a Washington state dentist. She stopped this program when she decided she “was not doing well.” According to Carolyn Bunker, an Aetna employee, claims for this treatment were submitted and denied by Aetna as not covered under the policy. In late May, 1980 Ms. Dallis attended a nutrition conference in Atlanta and heard about “Dr. Burton’s program” at the Immunology Researching Center, Ltd. (IRC) in Freeport, Bahamas. Shortly thereafter she saw a report on Dr. Lawrence Burton on the CBS television program “60 Minutes.”

Ms. Dallis attempted to make an appointment at the IRC through an Atlanta doctor, *549 Dr. Fried, but he was unable to do this immediately. Dr. Fried did, however, write a note for her, on one of his prescription forms, which said: “See Dr. Burton in Freeport, Bahamas — Milton Fried, M.D.” Dr. Fried told Ms. Dallis that he didn’t know anything about Dr. Burton’s program but that “there wasn’t anything for her from anyone else.” (Dr. Fried’s depo., p. 22).

Ms. Dallis called the IRC directly and was advised to send her medical records for evaluation. She did so and within twenty (20) days was informed that she had been accepted as a patient. She went to Freeport and began treatment immediately. Upon arrival Ms. Dallis paid a $300.00 evaluation fee and $2,200 for the first month’s therapy. Before beginning treatment Ms. Dallis did not contact Aetna to see if the expenses would be covered. During her deposition Ms. Dallis stated that she had no recollection as to whether the question of coverage “crossed [her] mind one way or the other. I just knew I wanted to be in on it____ It didn’t make any difference. I was going to get on the program.” (J. Dallis’ depo., pp. 30, 31).

Ms. Dallis began treatment at the IRC on July 2, 1980, and continued until December 1980. Sometime between September 19 and November 19, 1980 claims for this period were submitted to Aetna. On March 10, 1981 the claims were denied. Defendant bases this denial on the following exclusion contained in the policy:

EXCLUSIONS, LIMITATIONS AND PROVISIONS APPLICABLE TO ALL TITLES

No insurance is afforded under any Title as to charges ... (5) for care, treatment, services or supplies which are not necessary for the treatment of the injury or disease concerned, nor to the extent that any charges for care, treatment, services or supplies are unreasonable.

Ms. Dallis returned to the IRC in March of 1981. She continued treatment there, on and off, until December 1982. Ms. Dallis died on January 19, 1983.

The IRC began operations in March, 1977 and was an outgrowth of the Immunology Research Foundation (IRF) located in New York. Lawrence Burton- was Director of the IRF from 1973 until February 1977. While at IRF, Burton participated in experimental therapy of patients who had received orthodox cancer treatment. The IRF applied to the FDA for approval of their experimental therapy in 1974 but never received approval. The application was later withdrawn. Subsequently Dr. Burton and others decided to move to Freeport, Bahamas. Because the treatment had not been proven to be effective, the Bahamian Minister of Health placed certain restrictions on the treatment.

The nature of the treatment performed at the IRC is detailed in a pamphlet provided to prospective patients. Beginning at page 5, the pamphlet states: 3

“Immuno-Augmentative therapy is the result of more than 25 years of research by Dr. Burton. His initial work was in the inducement of tumors in laboratory animals and from that study, he developed a method of isolating and purifying anti-cancer substances in the blood.
In addition to discovering a blocking protein which prevents the immune mechanism from working, Dr. Burton found the factors within the blood that have an anti-cancer effect. His therapy includes a deblocking protein (an alpha 2 macroglobulin), tumor complement (complement 3), and tumor antibody fractions which include the alpha 2 macroglobulin, lgG, lgM, and IgA.”

The mechanics of the immune response are described on page 6 of the pamphlet as follows:

After the tumor cells develop in the body and begin to grow, the tumor cells *550 send out a signal which stimulates the body to produce tumor complement. The tumor complement activates tumor antibody. This activation of the tumor antibody results in tumor cell death. A byproduct of tumor cell death is a blocking protein which signals the immune mechanism to shut doors, by preventing the activation of the tumor antibody by the tumor complement.
However, the deblocking protein unites with the blocking protein, thereby neutralizing it and permitting the reactivation of tumor antibody by tumor complement.
All of the fractions used in the therapy are natural parts of the blood and therefore are non-toxic. Extensive testing for efficacy and toxicity is done prior to the addition of any new blood fraction to the therapy.
While in Freeport, patients are seen and tested daily at the Centre. The immuno-competence of the individual is tested at least once daily and then new therapy is prescribed.
Daily doses of fractions for the patients are determined by computer. In turn, the computer is used to track the results of the treatment.
Most patients must be prepared to stay a minimum of 6 to 8 weeks during their first visit____
Patients who have undergone the initial therapy take the fractions home with them along with computer projections of therapy.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Rockwell International Corp.
795 F. Supp. 1131 (N.D. Georgia, 1992)
Sabatier v. State Farm Mutual Automobile Insurance
592 A.2d 1098 (Court of Appeals of Maryland, 1991)
Shumake v. Travelers Insurance
383 N.W.2d 259 (Michigan Court of Appeals, 1985)
Park A. Dallis v. Aetna Life Insurance Company
768 F.2d 1303 (Eleventh Circuit, 1985)
Dallis v. Aetna Life Insurance
100 F.R.D. 765 (N.D. Georgia, 1984)

Cite This Page — Counsel Stack

Bluebook (online)
574 F. Supp. 547, 1983 U.S. Dist. LEXIS 12003, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dallis-v-aetna-life-insurance-gand-1983.